Causes and Prognosis of Visual Acuity Loss at the Time of Initial Presentation in Idiopathic Intracranial Hypertension

John J. Chen, Matthew J. Thurtell, Reid A. Longmuir, Mona K. Garvin, Jui-Kai Wang, Michael Wall, and Randy H. Kardon

1Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, United States
2Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
3Department of Neurology, University of Iowa, Iowa City, Iowa, United States
4Department of Veterans Affairs, Iowa City, Iowa, United States
5Department of Electrical and Computer Engineering, University of Iowa, Iowa City, Iowa, United States

PURPOSE. To determine the etiology and prognosis of visual acuity loss in idiopathic intracranial hypertension (IIH) at presentation and to provide objective measures to predict visual outcome.

METHODS. A retrospective review of 660 patients with IIH (2009–2013) identified 31 patients (4.7%) with 48 eyes having best-corrected visual acuity (BCVA) of 20/25 or worse on initial presentation. Fundus photography, optical coherence tomography (OCT) of the optic disc and macula, and perimetry were used to determine the causes and prognosis of vision loss. Segmentation of the macula OCT was performed using the Iowa Reference Algorithm to determine the retinal ganglion cell-inner plexiform layer complex (GCL-IPL) thickness.

RESULTS. Outer retinal changes alone caused decreased BCVA at initial presentation in 22 eyes (46%): subretinal fluid in 16, chorioretinal folds in 5, and peripapillary choroidal neovascularization in 1. The vision loss was reversible except for some eyes with chorioretinal folds. Optic neuropathy alone caused decreased BCVA in 10 eyes (21%) and coexisting outer retinal changes and optic neuropathy caused decreased BCVA in 16 eyes (33%). A GCL-IPL thickness less than or equal to 70 µm at initial presentation or progressive thinning of greater than or equal to 10 µm within 2 to 3 weeks compared with baseline correlated with poor visual outcome.

CONCLUSIONS. Visual acuity loss in IIH can be caused by both outer retinal changes and optic neuropathy. Vision loss from outer retinal changes is mostly reversible. The outcome of patients with coexisting outer retinal changes and optic neuropathy or optic neuropathy alone depends on the degree of optic neuropathy, which can be predicted by the GCL-IPL thickness.

Keywords: idiopathic intracranial hypertension, subretinal fluid, optic neuropathy, optical coherence tomography, ganglion cell layer

Idiopathic intracranial hypertension (IIH) is a condition of increased intracranial pressure of unknown cause producing papilledema and visual loss.1–3 The major morbidity of IIH is visual impairment, which can be progressive and insidious.4,5 The visual loss is often reversible if treatment is initiated in a timely fashion, but can be permanent in up to 40% of patients.5,6 The most common visual field defects are enlargement of the physiologic blind spot, nasal steps, and arcuate defects.7,8 If the disease remains untreated, the patient can develop severe irreversible visual field constriction.5 Visual field loss with decrease in visual acuity occurs with advancing optic nerve damage and can progress to blindness. However, some patients present to medical attention with decreased visual acuity. These patients pose a difficult dilemma to the physician, because some may have fulminant IIH, where the vision loss is due to severe papilledema and optic neuropathy;9–11 while others have vision loss from outer retinal changes in the macula.12,13

Past studies have reported that outer retinal changes in the macula associated with IIH include chorioretinal folds,14,15 hyperopic shift,16–18 hemorrhages,19,20 macular edema,19,21–23 subretinal fluid,24 or, rarely, subretinal neovascularization.19,22,25,26 Outer retinal changes in the macula in IIH have been reported to occur with an incidence ranging from 3.2% to 44%, largely dependent on the severity of IIH among the patients included and the methods used to assess for macular pathology.5,12,13,27 Subretinal fluid and macular exudates are common causes of visual acuity loss in IIH, and are often reversible with treatment.1,12,13,22–24,28 Therefore, distinguishing outer retinal changes from optic neuropathy as the cause of decreased visual acuity is important, because outer retinal changes in the macula affecting visual acuity may be largely reversible,24,28–31 whereas fulminant IIH with optic neuropathy and neuronal loss may require more aggressive management, such as immediate surgical intervention, to prevent further vision loss and irreversible blindness. It is difficult to detect optic neuropathy in IIH, because
papilledema obscures the nerve making pallor difficult to evaluate and also prevents accurate assessment of axonal loss by retinal nerve fiber layer (RNFL) thickness measurements determined by optical coherence tomography (OCT) due to the significant swollen axons of the optic nerve. In addition, thinning of the RNFL during the disease course may be due to improvement of papilledema or due to axon loss from worsening of the disease. Evaluating the integrity of the optic nerve in the setting of disc edema could be theoretically accomplished by analyzing the inner layers of the macula, specifically the ganglion cell layer-inner plexiform layer (GCL-IPL). Thinning of the macular GCL-IPL layer has been found to have a strong relationship with visual loss in optic nerve diseases such as glaucoma, optic neuritis, ischemic optic neuropathy, hereditary optic neuropathy, toxic optic neuropathy, and optic nerve glioma, and therefore can theoretically provide accurate measurement of neuronal loss in the presence of papilledema and allow early identification of patients with significant optic neuropathy caused by IIH.

The purpose of this study was to evaluate the prevalence, causes, and prognosis of visual acuity loss in IIH at presentation. In addition, we examined correlations between visual outcomes and GCL-IPL in order to predict reversibility in hopes of being able to identify patients that require urgent aggressive management.

**Materials and Methods**

**Subjects**

The study was approved by the University of Iowa (Iowa City, IA, USA) institutional review board and adhered to the tenets of the Declaration of Helsinki. A retrospective review of 660 patients with IIH (2009–2013) identified 31 patients (4.7%) with 48 eyes that had best-corrected or pinhole visual acuity of 20/25 or worse on presentation to our clinic. The average age of patients was 25 years (SD = 5.5; range, 13–39), with 4 males and 27 females. All patients met the modified Dandy criteria for idiopathic intracranial hypertension. Patients were excluded if there was coexisting ophthalmic disease unrelated to IIH or another cause for decreased vision besides IIH. Patients were also excluded if there was a nonorganic component to their vision loss or if their visual field testing was unreliable.

All of the patients were treated medically with acetazolamide and/or topiramate and/or surgical intervention with optic nerve sheath fenestration and/or ventriculoperitoneal shunting.

All patients underwent a full neuro-ophthalmologic examination at each visit, which included visual acuity, pinhole visual acuity, and automated Humphrey perimetry (24-2 SITA-standard) and/or kinetic Goldmann perimetry. Goldmann perimetry was typically obtained in patients with visual acuity equal to or worse than 20/40 or in patients who had unreliable automated Humphrey perimetry. For kinetic Goldmann visual field testing, responses to the V4e, I4e, I2e, and I1e stimuli were routinely assessed. Fundus photographs and OCT imaging were performed at the majority of visits. Average follow-up was 4.97 months (SD = 2.14; range, 2–12 months).

**Optical Coherence Tomography**

Optical coherence tomography imaging was performed after pupillary dilatation using SD-OCT (Cirrus 4000, Cirrus software version 6.0; Carl Zeiss Meditec, Dublin, CA, USA and/or Spectralis HRA-OCT, Spectralis software version 5.5; Heidelberg Engineering, Heidelberg, Germany). Images with signal strength less than 7 were excluded.
on the optic disc for optic nerve analysis and centered on the fovea for macula analysis.

**Macular Segmentation and Measurement**

Commercially available segmentation algorithms to assess the GCL-IPL complex are prone to failure when there is significant optic disc edema (Fig. 1). This problem can be overcome by using the Iowa Reference Algorithm (in the public domain, http://www.biomed-imaging.uiowa.edu/downloads), a fully three-dimensional (3D), automated algorithm,46–49 which can accurately measure the macular GCL-IPL complex in the presence of optic disc edema. The incorporation of 3D information allows the Iowa reference algorithm to decrease segmentation error (Fig. 1).46–48 The boundaries of the macular GCL-IPL were defined by the junction between the retinal nerve fiber and ganglion cell layers and the junction between the inner plexiform and inner nuclear layers. The automated segmented layers were inspected for errors and manually corrected if present except for three of the eyes with chorioretinal folds, which were deemed too difficult to correct accurately.

**Defining Etiology of Vision Loss**

The etiology of vision loss was divided into three main categories: outer retinal changes in the macula alone, combination of outer retinal changes and optic neuropathy, and optic neuropathy alone. The category of outer retinal changes was further divided into three subcategories: subretinal fluid, chorioretinal folds, and choroidal neovascularization. Subretinal fluid was identified on OCT as accumulation of subfoveal fluid. In addition, patients with disruption of the photoreceptor layer on OCT were included in the subcategory of subretinal fluid. Photoreceptor disruption was used as an indicator of recent subretinal fluid because reconstitution of the photoreceptor layer typically takes 1 to 4 weeks after resolution of subretinal fluid in IIH (manuscript in preparation), as has been observed after resolution of subretinal fluid in central serous retinopathy.50 Fundus photographs were also used to identify exudates within the macula that indicated...
current or prior subretinal fluid. Chorioretinal folds were identified on OCT and fundus photography. A single patient had choroidal neovascularization affecting visual acuity, which was evident on OCT and fundus photography.

Optic neuropathy was identified retrospectively by either the development of optic disc pallor on fundus photography or an average GCL-IPL thickness of less than 70 μm. For comparison, the 95% confidence interval for average GCL-IPL thickness in a healthy young adult is 75 to 95 μm (Zeiss).

Although many patients likely had hyperopic shift from posterior globe flattening, these patients were not captured because only patients with best corrected or pinhole visual acuity of 20/25 or worse were included. Patients with hyperopic shift affecting visual acuity achieve a visual acuity of better than 20/25 with refraction or pinhole.

**Defining Visual Outcomes**

The visual outcomes were analyzed separately for final best corrected or pinhole visual acuity and visual field loss on the final visual field. The visual acuity was expressed as the logMar for analysis. Goldmann perimetry was quantified in an objective manner by measuring and summing the area of each isopter using ImageJ software (http://imagej.nih.gov/ij/; provided in the public domain by the National Institutes of Health, Bethesda, MD, USA) to obtain the visual field volume. Only responses to the I4e, I2e, and I1e stimuli were routinely measured in all patients and, consequently, only these were included to quantify the Goldmann visual field volume. The isopters were manually traced using ImageJ. Each isopter was given a relative weight to account for the relative luminance of the energy stimulus (14e = 1000, 12e = 100, 14e = 10). The volume of the visual field was calculated by multiplying the relative weights with the area of each isopter and summing the values. The Goldmann perimetry results were ranked based on the measured visual field volumes. The automated Humphrey perimetry results were ranked based upon mean deviation. Rank ordering of automated and kinetic visual fields as one dataset was accomplished by learning how to relate the two types of perimetry from cases where both were performed on similar dates.

To provide an estimate of vision loss within the ranked fields and confirm the validity of this method of ranking of the fields, the final visual fields were also assigned a severity of visual field loss as described by Wall and George. According to the Wall and George classification, grade 5 is blinding visual field loss, grade 4 is marked visual field loss, grade 3 is moderate visual field loss, grade 2 is mild visual field loss, grade 1 is minimal visual field loss, and grade 0 is a normal visual field. The criteria for each of these categories for both manual and automated visual fields can be seen in the manuscript, Wall and George, 1991.

The final logMar visual acuity and the rank order of final visual field outcomes were compared against the initial visual acuity, initial visual field, initial GCL-IPL thickness, GCL-IPL thickness at 2 to 3 weeks, final GCL-IPL thickness, change of GCL-IPL thickness at 2 to 3 weeks, and the total change of GCL-

---

**Figure 4.** Example of a patient with decreased visual acuity from subretinal fluid. On presentation, the patient had visual acuities of 20/200 in the right eye and 20/125 in the left eye, grade IV optic disc edema in both eyes (A), and constricted Goldmann visual fields (B).

Optical coherence tomography of the macula demonstrates subretinal fluid in both eyes (C). The GCL-IPL complex was segmented with the Iowa Reference Algorithm (C) and the average thickness was normal in both eyes (D). After 2 months, visual acuity improved to 20/20 in both eyes, the optic disc edema was significantly improved (E), and the Goldmann visual fields were normal (F). The GCL-IPL was segmented using the Iowa Reference Algorithm (G) and the average thickness remained normal in both eyes (H).
FIGURE 5. Example of a patient with decreased visual acuity from a combination of subretinal fluid and optic neuropathy with a poor outcome. On initial presentation, the patient had visual acuities of 20/125 in the right eye and 20/30 in the left eye, grade IV optic disc edema in both eyes (A), and constricted, scotomatous Goldmann visual fields (B). Optical coherence tomography of the macula at presentation demonstrates subretinal fluid in both eyes (C). The GCL-IPL complex was segmented with the Iowa Reference Algorithm (C) and the average thickness was normal in both eyes (D). After 2 weeks, visual acuity improved to 20/40 in the right eye and 20/25 in the left eye (E), but the Goldmann visual fields continued to show significant constriction (F). The GCL-IPL was segmented with the Iowa Reference Algorithm (G) and the average thickness was significantly...
decreased by 16.9 μm in the right and 10.6 μm in the left eye (H). After 3 months, visual acuity had worsened to light perception in both eyes and the optic discs developed severe pallor after resolution of the optic disc edema (I). The GCL-IPL was very thin, showing a 36.7 μm reduction in the right eye and 34.8 μm reduction in the left eye when compared with the initial GCL-IPL thickness (J).

IPL thickness. Visual acuity outcomes were analyzed with linear regression. The Spearman correlation coefficient was calculated for comparisons against the rank order of the visual fields.

RESULTS

Causes and Prognosis of Vision Loss From IIH at Presentation

Outer retinal changes alone caused decreased visual acuity at presentation in 22 eyes (46%): subretinal fluid in 16, chorioretinal folds in 5, and peripapillary choroidal neovascularization in 1. Optic neuropathy alone caused decreased visual acuity at presentation in 10 eyes (21%), and coexisting outer retinal changes and optic neuropathy caused decreased visual acuity in 16 eyes (33%; Fig. 2). The majority of eyes presented with modified Frisen grade IV optic disc edema or worse, except for eyes presenting with chorioretinal folds, significant coexisting optic disc pallor, and choroidal neovascularization.52

The outer retinal changes in the macula that were responsible for visual acuity loss were largely reversible except for chorioretinal folds. Among the nine patients (16 eyes) with subretinal fluid or evidence of prior subretinal fluid (photoreceptor disruption), all achieved best corrected or pinhole visual acuity of 20/20 with medical treatment alone. One patient with subretinal fluid underwent optic nerve sheath fenestration in one eye early in their course due to intolerance to acetazolamide treatment and recovered to 20/20 vision (Figs. 3, 4). A single patient developed peripapillary choroidal neovascularization with subfoveal fluid and presented with a visual acuity of 20/125, which improved to 20/25 after receiving intravitreal bevacizumab. Among the three patients (five eyes) with chorioretinal folds, the visual acuities did not significantly improve despite treatment of IIH in four of five eyes (Fig. 5).

The final visual acuity of patients presenting with optic neuropathy alone or a combination of outer retinal changes in the macula and optic neuropathy was variable, ranging from 20/25 to light perception, with most of the eyes recovering to 20/60 or better (Figs. 3, 5).

The visual field outcomes of the 48 eyes were put in rank order based on the degree of visual loss on the final visual field and compared against the Wall and George classification system (Fig. 6).7 This was done because some of the eyes had kinetic Goldmann perimetry, whereas others had static perimetry. The rank order was a means of combining the visual field information, regardless of the perimetry type used. There was a strong correlation between the ranked visual fields and the degree of visual loss (Fig. 6).7

Nine of 10 eyes with optic neuropathy were in the bottom half of the ranked visual field outcomes and, therefore, had significant visual field loss with an average of grade 3.2 visual field loss, according to the Wall and George classification (SD ± 1.7; range, 0–5; Fig. 6). Eleven of 15 eyes with combined macular changes and optic neuropathy were in the bottom half of the ranked visual field outcomes, and overall had grade 2.4 vision loss on average (SD ± 1.4, range, 0–5). Patients with subretinal fluid alone achieved nearly normal visual fields and were in the upper half of the ranked visual field outcomes with grade 0.76 vision loss on average (SD ± 0.75, range, 0–2; Fig. 6). Among the 24 eyes in the bottom half of the ranked visual field outcomes, 15 received both medical and surgical intervention (62.5%). Two of the 24 eyes with better visual field outcomes received both medical and surgical intervention (8.3%) and the 22 other eyes with better visual field outcome received medical treatment alone.

GCL-IPL Thickness in Predicting Visual Outcome

There was a weak correlation between the final visual acuity and the macular GCL-IPL thickness at presentation ($r^2 = 0.392, P < 0.001$), at 2 to 3 weeks ($r^2 = 0.313, P < 0.001$), and at the final visit ($r^2 = 0.345, P < 0.001$). The correlation was skewed, because there were only 15 eyes that did not improve to a visual acuity of 20/20 with treatment.

There was a significant correlation between the macular GCL-IPL thickness and the rank order of visual field outcomes (Fig. 7; Table). At presentation, five eyes had a GCL-IPL thickness of less than 70 μm and all of these eyes had poor visual field loss, according to the Wall and George classification (SD ± 2.4; range, 0–5).

![Figure 6](https://example.com/figure6.png)

**Figure 6.** Ranked visual field outcomes compared with the grade of vision loss according to the Wall and George classification. The visual field outcomes of each of the eyes were put in rank order based on the degree of visual loss on the final visual field and compared against the grade of vision loss. The cause of vision loss was color coded so that the separate categories of vision loss could be compared against the ranked visual field outcomes and the grade of vision loss.
A. Presenting GCL-IPL thickness

B. GCL-IPL at 2-3 weeks

C. GCL-IPL change at 2-3 weeks

D. Final GCL-IPL thickness

E. GCL-IPL final change

Figure 7. Categories of vision loss and GCL-IPL thickness used as predictors of visual field outcomes. The ranked final visual field outcomes were compared against the initial GCL-IPL thickness (A), GCL-IPL thickness at 2 to 3 weeks (B), change in GCL-IPL thickness at 2 to 3 weeks (C), final GCL-IPL thickness (D), and change in GCL-IPL thickness at final visit (E).

<table>
<thead>
<tr>
<th>Table. GCL-IPL Thickness Compared Against Visual Field Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>All eyes</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Subretinal fluid</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Optic neuropathy</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Combined macular changes and optic neuropathy</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

$R$, Spearman’s correlation coefficient comparing GCL-IPL thickness and final visual field outcome.
visual field outcomes, which led to a weak correlation between initial GCL-IPL thickness and final visual field outcome (Spearman Correlation = 0.439, P = 0.005360; Fig. 7A; Table). The rest of the patients had a normal GCL-IPL thickness at presentation, which did not significantly correlate with final visual field outcome. At 2 to 3 weeks, there was a strong correlation between the GCL-IPL thickness and final visual field outcome (Spearman Correlation = 0.76, P < 0.0001; Fig. 7B; Table) and a decrease in the GCL-IPL thickness of more than 10 μm during this period was associated with a poor visual field outcome among eyes presenting with a normal GCL-IPL thickness (Fig. 7C).

When the categories of vision loss were examined individually, patients with optic neuropathy alone had a significant correlation between final visual outcome and GCL-IPL thicknesses at all time points (Table). Patients with a combination of optic neuropathy and macular changes had a significant correlation between final visual outcome and both GCL-IPL thickness at 2 to 3 weeks and final GCL-IPL thickness, while the initial GCL-IPL thickness had a negative correlation (Table). Patients with macular changes alone had no correlation between GCL-IPL thickness and final visual outcome at any time point (Table).

**Initial Visual Acuity and Visual Field in Predicting Visual Outcomes**

Overall, initial visual acuity did not have a significant correlation with final visual acuity (r² = 0.185, P = 0.091). However, when each category of vision loss was compared separately, patients with optic neuropathy alone had a significant correlation between initial and final visual acuity (r² = 0.4691, P = 0.029). There was no correlation between initial and final visual acuities for the other categories of vision loss.

In contrast, the initial visual field had a significant correlation with final visual field outcome (Spearman Correlation = 0.667, P < 0.0001; Fig. 8).

When each category of vision loss was analyzed separately, a significant positive correlation was found between initial and final visual field rank in eyes with a combination of macular changes and optic neuropathy (Spearman Correlation = 0.780, P < 0.0001) and in eyes with optic neuropathy alone (Spearman Correlation = 0.952, P < 0.0001). Patients with outer retinal changes alone showed no correlation between the initial and final visual fields (Spearman Correlation = 0.294, P = 0.262).

**DISCUSSION**

Our study found that 4.7% of patients with IIH referred to a tertiary center had decreased visual acuity on presentation, defined as best corrected vision of 20/25 or worse. Most (83.3%) of these patients had Frisén grade IV or V optic disc edema. Approximately one-third of these patients had outer retinal changes in the macula, one-third had optic neuropathy, and one-third had a combination of outer retinal changes in the macula and optic neuropathy as the cause of decreased visual acuity.

Our study demonstrates that outer retinal changes in the macula are largely reversible except in the case of chorioretinal folds, which can cause a mild persistent decrease in visual acuity in some instances. Eight of nine patients with subretinal fluid had a full recovery of vision with medical management alone. One patient with subretinal fluid underwent early optic nerve sheath fenestration due to poor tolerance of acetazolamide. These findings are similar to those of a prior study where six of seven patients with subretinal fluid associated with papilledema showed improvement in visual acuity upon resolution of the subretinal fluid with acetazolamide alone.24

In our study, the outcomes of patients with optic neuropathy alone or a combination of optic neuropathy and outer retinal changes were largely dependent on the degree of optic neuropathy, which could be predicted by the GCL-IPL thickness on SD-OCT macular scans. We found that the GCL-IPL thickness at presentation was often normal and, therefore,
the initial GCL-IPL thickness was not useful in predicting visual outcome for the majority of patients. However, there was a subset of eyes that had an initial GCL-IPL thickness of less than 70 μm that all had poor visual outcomes. These patients may require immediate aggressive intervention to preserve their remaining vision and ganglion cells. In patients presenting with a normal GCL-IPL thickness, serial GCL-IPL OCT analysis at 2 to 3 weeks was more helpful, where a drop of more than 10 μm compared with the initial GCL-IPL thickness was strongly associated with a poor visual outcome. By combining the subset of eyes with an initial GCL-IPL thickness of less than 70 μm with the eyes having an early decrease in GCL-IPL thickness of more than 10 μm, all eyes with a poor final visual outcome could be predicted within 2 to 3 weeks of presentation.

While the presenting visual acuity had no correlation with final visual acuity in the entire cohort, patients with vision loss from optic neuropathy alone did demonstrate a significant correlation. This supports the notion that vision loss from outer retinal layer changes in the macula is typically reversible, while vision loss from optic neuropathy and inner retinal layer change is less reversible. There was also a correlation between the initial visual field and visual field outcome. This correlation was dominated by patients with optic neuropathy or optic neuropathy in combination with outer retinal changes in the macula.

Patients receiving both medical and surgical management had a worse outcome, likely because of the severity of the disease that led to the decision of surgical intervention rather than surgery causing a worse outcome. However, our findings do suggest that medical therapy alone is often adequate for patients with severe papilledema, because the vast majority of patients in this study had grade IV optic disc edema and the majority of patients with good visual outcomes were treated with medication alone. The idiopathic intracranial hypertension treatment trial (IIHTT) supports the efficacy of acetazolamide in the treatment of IIH. The trial examined the effects of acetazolamide against placebo in 165 patients with mild visual field loss (−2 to −7 dB) perimetric mean deviation in the worse eye) from IIH and found six treatment failures in the placebo group and only one treatment failure in the acetazolamide group as defined by a worsening of 2 to 3 dB from baseline. All of the patients with treatment failure had high grade papilledema. Interestingly, nearly 30% of the study eyes in the IIHTT had BCVA worse than 20/20 on initial presentation. Although these patients have not yet been individually evaluated to determine the cause of decreased visual acuity, it is possible that many of them had subtle macular changes that would be amenable to medical treatment.

The greatest limitations to our study are its retrospective nature and variable length of follow-up. The majority of patients were treated in a similar fashion with escalating doses of acetazolamide to a goal of 4000 mg a day within 2 to 4 weeks of diagnosis, then referral for surgical intervention with optic nerve sheath fenestration if their vision continued to worsen. However, some could not tolerate medication and were referred for surgery earlier. Others were referred for surgical intervention earlier because of the perceived severity of the disease. Therefore, there were treatment differences in some of the patients that may or may not have influenced the final visual outcome.

It is also important to note that commercially available macular segmentation algorithms will commonly fail in patients with significant optic disc edema, giving artificially thin inner retinal layer measurements. Therefore, measurements of GCL-IPL complex thickness in IIH should be obtained using more robust 3D segmentation algorithms, such as the Iowa Reference Algorithm used in this study.

In summary, outer retinal changes in the macula causing decreased visual acuity in IIH patients at presentation are largely reversible except for chorionetinal folds that can cause mild persistent decreased vision in some instances. The visual prognosis of IIH patients with a combination of outer retinal changes in the macula and optic neuropathy or optic neuropathy alone is largely dependent on the degree of optic neuropathy, which can be predicted by OCT measurement of the GCL-IPL thickness. A GCL-IPL thickness of less than 70 μm early in the disease course or early progressive thinning of more than 10 μm during the first 2 to 3 weeks from presentation are correlated with a poor visual outcome and may indicate the need for more aggressive management.

Acknowledgments
Supported by C9251-C, Rehabilitation Research & Development (RR&D), VA-ORD (RK, MG); R01 EY023279, National Eye Institute (NEI) Subcontract for 3U10 EY017281 (RK, MG, MT, RL); GG005828 with Columbia University for 5 R01 EY02211536, Subcontract NEI (RK); W81XWH-10-1-0756, Department of Defense (RK); 2R01 EY018853, NEI Subcontract for 3U10 (MG); EY017281, NEI (MG); C7098-R Merit Review Grant from the Department of Veterans Affairs (MW); and IU10EY017281-01A1 (NORDIC) National Institute of Health (MW).

Disclosure: J.J. Chen, None; M.J. Thurtell, None; R.A. Long-muir, None; M.K. Garvin, None; J.-K. Wang, None; M. Wall, None; R.H. Kardon, None

References


